… It appears that the kinase activity of LRRK2 is linked to its ability to self-associate. We have developed an assay … whether it is present alone (as a monomer) or in a large complex with multiple LRRK2 molecules, and then directly … assess these different activities of LRRK2 in parallel, and how they correlate with its ability to self-associate, since …

… This Sunday, nearly 48,000 athletes will take to the streets of New York City's five boroughs for the ING … NYC Marathon. While an impressive 26.2 miles is a proud accomplishment for most, there are some runners, like Team Fox … idea of running a full 26.2 miles at a 6:52/mile pace (or faster!) can be daunting at times, doing so in order to …

… Study Rationale: The protein alpha-synuclein forms aggregates in the brains of people with Parkinson’s. Here, we will not look at the end stage of protein … caused by exposure of healthy neurons, or brain cells, to native forms of alpha-synuclein secreted by neurons …

… disease-causing mutations and genetic variants. In addition to producing disease pathology, these genetic lesions can … also contributes to the disease, and we have discovered compounds that improve the function of these target genes. … of Parkinson’s disease:  Based on our understanding of how these compounds work, we believe that our drug …

… development of an oral drug aimed at alleviating the symptoms of Parkinson's disease (PD).  MJFF has committed more than $1.2 million toward this effort. Envoy is developing compounds that target an area of the brain called the indirect pathway, the …

… Disorder Society International Congress in Dublin, Ireland. Today, nearly 2,000 movement disorder specialists packed the … as inhaled formulations of the drug, pump systems, and a combination pump/patch approved for use in diabetes, have … approach to PD. (Note: Austrian biotech AFFiRiS AG, however, has just enrolled participants in an early clinical …